NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their price objective on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 1.2 %

NovaBay Pharmaceuticals stock opened at $0.62 on Friday. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08. The business has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $0.88. The company has a market cap of $3.03 million, a P/E ratio of -0.01 and a beta of 0.65.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.